The company said, “The focus of the Company remains on generating and disclosing pivotal clinical data to demonstrate the clinical benefit of our DRP guided therapies. Accordingly, we expect to announce interim data from the DRP-guided Phase 2 clinical trial of stenoparib in advanced ovarian cancer during the second quarter of 2024. We believe that this milestone is particularly significant as it will provide further insights into stenoparib’s potential to meet the unmet needs in the treatment of advanced ovarian cancer.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALLR:
- Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
- Allarity Therapeutics Announces CMO Marie Foegh’s Departure
- Allarity Therapeutics Adjusts Convertible Notes and Updates Presentation
- Allarity Therapeutics to Present at Biomarkers 2024
- Allarity Therapeutics’ Strategic Financial Moves and Securities Adjustments
